Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia

Inclusion Criteria: Diagnosis of refractory or relapsed ALL (acute lymphocytic leukemia) Age greater than or equal to 15 years No chemotherapy, radiation, or major surgery within 2 weeks prior to first dose of study drug and recovered from toxic side effects of that therapy, unless treatment is indicated due to progressive disease. No investigational therapy within 4 weeks of first dose of study drug ECOG performance status (PS) 0 to 2. Adequate liver function Adequate renal function Signed informed consent Exclusion Criteria: Concommitant therapy that includes other chemotherapy that is or may be active against ALL (except central nervous system [CNS] therapy) Any condition which in the opinion of the investigator, places the subject at unacceptable risk if he/she were to participate in the study. Cardiac ejection fraction less than 40% Clinically relevant serious co-morbid medical conditions. Pregnant, lactating or not using adequate contraception. Known allergy to doxorubicin or anthracyclines.